Moderna Flu Vaccine: Positive Phase 3 Results
- Moderna recently released promising phase 3 trial data for its messenger RNA (mRNA) vaccine targeting seasonal influenza.
- According to Moderna, the mRNA flu vaccine demonstrated a strong immune response compared to a currently licensed standard-dose influenza vaccine.
- If approved, Moderna's mRNA seasonal influenza vaccine could become a key tool in preventing future flu outbreaks, potentially offered as a combination shot alongside its COVID-19 vaccine.
Moderna‘s mRNA seasonal influenza vaccine shows remarkable results in phase 3 trials, marking a significant step in the fight against the flu. The data indicates a robust immune response compared to existing vaccines, potentially paving the way for a dual COVID-19/flu shot. the company is now preparing to seek regulatory approval for this promising vaccine candidate. This breakthrough could transform seasonal influenza prevention. News Directory 3 brings you the latest updates on Moderna’s progress and its plans for the future. Learn how this could lead to better protection against both COVID-19 and seasonal flu. Discover what’s next and how this new vaccine could impact public health.
Moderna reports positive phase 3 data for flu vaccine candidate
Updated July 03, 2025
Moderna recently released promising phase 3 trial data for its messenger RNA (mRNA) vaccine targeting seasonal influenza. These results could accelerate the development of Moderna’s combined COVID-19 and influenza vaccine.
According to Moderna, the mRNA flu vaccine demonstrated a strong immune response compared to a currently licensed standard-dose influenza vaccine. The company plans to engage wiht regulatory bodies to submit applications for approval of the new seasonal influenza vaccine.
What’s next
If approved, Moderna’s mRNA seasonal influenza vaccine could become a key tool in preventing future flu outbreaks, potentially offered as a combination shot alongside its COVID-19 vaccine.